Aethlon Medical (AEMD) AI Stock Analysis

• Market Cap: $3.02M
• Dividend Yield: N/A
• Average Volume (3M): 190.55K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.10
• Revenue Growth: -100.00%
• EPS Growth: 68.26%
• Country: US
• Employees: 14
• Sector: Healthcare
• Sector Strength: 39
• Industry: Medical - Devices
• EPS (TTM): -3.22
• Shares Outstanding: 2,585,316
• 10 Day Avg. Volume: 456,013
• 30 Day Avg. Volume: 190,549
• PEG Ratio: <0.01
• Price to Book (P/B): <0.01
• Price to Sales (P/S): 0.00
• P/FCF Ratio: >-0.01
• Enterprise Value/Market Cap: -1.60K
• Enterprise Value/Revenue: -28.17K
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: 151.51
• 1Y Price Target: $1.50
• Price Target Upside: 26.05% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 2

• Rating: 38 Underperform
• Price Target: ―

Aethlon Medical's overall stock score is low due to significant financial challenges, including persistent losses and cash flow issues. The technical indicators suggest negative momentum, and the valuation is unattractive given the negative P/E ratio and lack of dividends. While the earnings call presented some positive strategic efforts, such as cost reduction and trial advancements, the hurdles in clinical trials and financial constraints weigh heavily on the stock's outlook.

Positive Factors

Clinical Trials

Significant progress was made with Aethlon's oncology program, including the first treatment of a patient with the company's Hemopurifier.

Product Innovation

The Hemopurifier's potential to improve outcomes in the treatment of people with viral infections, cancer, and now results with perfusion of discarded kidneys is underappreciated.

Regulatory Approvals

AEMD received formal approval from India's Central Drugs Standard Control Organization to initiate a similar oncology trial at Medanta Medicity Hospital.

Negative Factors

Commercialization Challenges

The path to commercialization for the Hemopurifier remains long and uncertain.

Financial Performance

The company reported a GAAP loss per share wider than expectations and is pre-revenue.

Investment Risks

Risks to our investment thesis include failure of clinical trials, regulatory requirements for additional clinical studies, an untested commercialization strategy, failure of products to show sufficient competitive differentiation in targeted product indications, intellectual property expiry or invalidation, potential to raise additional funds under poor market conditions, and potential failure to meet Nasdaq minimum bid.

Aethlon Medical Business Overview & Revenue Model

Company Description

Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.

How the Company Makes Money

Aethlon Medical makes money through the development and commercialization of its Hemopurifier product, targeting both therapeutic and diagnostic markets. Revenue is primarily generated from grants, research and development contracts, and potential sales or licensing of its proprietary technology. As a company focused on early-stage biotechnology, Aethlon also relies on government funding and partnerships with research institutions to support its development efforts. Key factors contributing to its earnings include the expansion of its product applications, regulatory approvals, and strategic collaborations that enhance its market reach and product development pipeline.

Aethlon Medical Financial Statement Overview

Summary

Aethlon Medical faces significant financial challenges, with no revenue growth and persistent losses. The balance sheet suggests limited financial flexibility despite low leverage. Cash flow issues exacerbate these concerns, with substantial cash outflows overshadowing financing efforts. The company needs to address its revenue generation and operational efficiency to improve its financial standing.

Income Statement

Aethlon Medical's income statement reveals significant challenges, with consistent negative gross profit and net income across both TTM and annual reports. The absence of revenue in the latest TTM indicates a severe downturn. Persistent negative EBIT and EBITDA margins highlight ongoing operational inefficiencies, with no visible improvement in revenue growth.

Balance Sheet

The balance sheet shows a moderate equity position with a relatively stable debt level. The Debt-to-Equity ratio remains low, indicating conservative leverage. However, the equity ratio suggests reliance on stockholder equity for asset financing, which could limit future growth potential. Despite a sizable cash position, the company's assets are declining, hinting at potential liquidity concerns.

Cash Flow

Cash flow analysis indicates severe cash management issues, with negative free cash flow and operating cash flow across periods. The large discrepancy between operating cash flow and net income raises concerns about the sustainability of operations. Despite positive financing cash flow, likely from equity issuance, the free cash flow remains negative, reflecting ongoing cash burn.

Breakdown	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	0.00	0.00	574.25K	294.17K	659.10K
Gross Profit	0.00	-359.00K	308.94K	139.95K	659.10K
EBITDA	0.00	-11.85M	-11.66M	-10.30M	-7.85M
Net Income	-13.39B	-12.21M	-12.03M	-10.42M	-7.89M
Balance Sheet
Total Assets	7.36B	8.25M	17.51M	19.42M	10.67M
Cash, Cash Equivalents and Short-Term Investments	5.50B	5.44M	14.53M	17.07M	9.86M
Total Debt	649.75M	940.32K	1.21M	729.41K	42.54K
Total Liabilities	2.24B	2.48M	2.44M	2.43M	1.38M
Stockholders Equity	5.12B	5.77M	15.06M	17.13M	9.43M
Cash Flow
Free Cash Flow	-7.65B	-10.38M	-11.45M	-10.12M	-6.82M
Operating Cash Flow	-7.65B	-10.13M	-10.51M	-9.77M	-6.76M
Investing Cash Flow	0.00	-250.87K	-943.11K	-349.19K	-59.88K
Financing Cash Flow	7.73B	1.29M	8.91M	17.37M	7.13M

Aethlon Medical Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.19
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AEMD, the sentiment is Negative. The current price of 1.19 is below the 20-day moving average (MA) of 1.60, below the 50-day MA of 2.48, and below the 200-day MA of 3.49, indicating a bearish trend. The MACD of -0.39 indicates Positive momentum. The RSI at 30.37 is Neutral, neither overbought nor oversold. The STOCH value of 11.90 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AEMD.

Aethlon Medical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AYTU	60 Neutral	$14.50M	―	3.29%	―	-26.17%	―
Sector *	52 Neutral	$7.45B	0.27	-61.87%	2.30%	16.62%	1.04%
TRIB	49 Neutral	$13.66M	―	77.20%	―	8.31%	9.98%
BNGO	41 Neutral	$11.07M	―	-127.82%	―	-24.04%	84.11%
MYNZ	41 Neutral	$5.34M	―	-809.29%	―	―	―
AEMD	38 Underperform	$3.02M	―	-245.88%	―	-100.00%	68.26%
PPBT	35 Underperform	$6.96M	―	-12.35%	―	―	71.57%

Aethlon Medical Corporate Events

Aethlon Medical Achieves Milestone in Oncology Trials

In its recent financial release, Aethlon Medical reported a significant milestone in its oncology trials in Australia, announcing the first patient treated with the Hemopurifier for solid tumors not responding to anti-PD-1 antibodies on January 29, 2025. The company has also implemented strategic cost-cutting measures, reducing operating expenses by 50% from the previous year, and made protocol amendments to accelerate trial timelines and improve patient enrollment. These developments are crucial for enhancing the company’s clinical program efficiency and potentially improving therapeutic responses in future oncology efficacy trials.